Modulation of the Human T Cell Response by a Novel Non-Mitogenic Anti-CD3 Antibody

The agonistic anti-human CD3ε antibody (Ab), OKT3, has been used to control acute transplant rejection. The in vivo administration of OKT3 was previously shown to induce the partial depletion of T cells and unresponsiveness (anergy) in the remaining CD4+ T cells. However, this therapy is also associated with the systemic release of several cytokines, which leads to a series of adverse side effects. We established a novel anti-human CD3ε Ab, 20-2b2, which recognized a close, but different determinant on the CD3ε molecule from that recognized by OKT3. 20-2b2 was non-mitogenic for human CD4+ T cells, could inhibit the activation of T cells in vitro, and induced T cell anergy in in vivo experiments using humanized mice. Cytokine release in humanized mice induced by the administration of 20-2b2 was significantly less than that induced by OKT3. Our results indicated that the CD3ε molecule is still an attractive, effective, and useful target for the modulation of T cell responses. The establishment of other Abs that recognize CD3ε, even though the determinant recognized by those Abs may be close to or different from that recognized by OKT3, may represent a novel approach for the development of safer Ab therapies using anti-CD3 Abs, in addition to the modification of OKT3 in terms of the induction of cytokine production.

[1]  C. Chen,et al.  Novel CD3‐specific antibody induces immunosuppression via impaired phosphorylation of LAT and PLCγ1 following T‐cell stimulation , 2014, European journal of immunology.

[2]  Aaron J. Martin,et al.  Manipulating T cell-mediated pathology: targets and functions of monoclonal antibody immunotherapy. , 2013, Clinical immunology.

[3]  Chen Chen,et al.  Inhibition of T cell activation through down-regulation of TCR-CD3 expression mediated by an anti-CD90 Ab. , 2011, Immunology letters.

[4]  P. van Endert,et al.  Human CD3 Transgenic Mice: Preclinical Testing of Antibodies Promoting Immune Tolerance , 2011, Science Translational Medicine.

[5]  K. Herold,et al.  Anti‐CD3 mAbs for treatment of type 1 diabetes , 2009, Diabetes/metabolism research and reviews.

[6]  J. Shimizu,et al.  In vivo expansion of CD4+Foxp3+ regulatory T cells mediated by GITR molecules. , 2008, Immunology letters.

[7]  B. Scallon,et al.  Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody. , 2006, International immunopharmacology.

[8]  B. Bisikirska,et al.  TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. , 2005, The Journal of clinical investigation.

[9]  S. Popma,et al.  Anti-CD3 antibodies OKT3 and hOKT3gamma1(Ala-Ala) induce proliferation of T cells but impair expansion of alloreactive T cells; aspecifc T cell proliferation induced by anti-CD3 antibodies correlates with impaired expansion of alloreactive T cells. , 2005, International immunopharmacology.

[10]  L. Chatenoud.  Anti-CD3 antibodies: towards clinical antigen-specific immunomodulation. , 2004, Current opinion in pharmacology.

[11]  A. Weiss,et al.  Jurkat T cells and development of the T-cell receptor signalling paradigm , 2004, Nature Reviews Immunology.

[12]  J. Bluestone,et al.  Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-Ala) , 2003 .

[13]  J. Bluestone,et al.  Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). , 2003, The Journal of clinical investigation.

[14]  P. Parren,et al.  In vitro characterization of five humanized OKT3 effector function variant antibodies. , 2000, Cellular immunology.

[15]  J. Phillips,et al.  Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. , 1999, Transplantation.

[16]  C. Anasetti,et al.  HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. , 1999, Transplantation.

[17]  P. Allen,et al.  Molecular basis for the lack of T cell proliferation induced by an altered peptide ligand. , 1998, International immunology.

[18]  R. Schwartz,et al.  Models of T Cell Anergy: Is There a Common Molecular Mechanism? , 1996 .

[19]  A. Necker,et al.  Reactivity of mouse T-cell hybridomas expressing human Vbeta gene segments with staphylococcal and streptococcal superantigens , 1996, Infection and immunity.

[20]  Paul M. Allen,et al.  Partial T cell signaling: Altered phospho-ζ and lack of zap70 recruitment in APL-induced T cell anergy , 1994, Cell.

[21]  J. Davoust,et al.  Evidence for protein tyrosine kinase involvement in ligand-induced TCR/CD3 internalization and surface redistribution. , 1994, Journal of immunology.

[22]  J. Bluestone,et al.  A NON‐ACTIVATING “HUMANIZED” ANTI‐CD3 MONOCLONAL ANTIBODY RETAINS IMMUNOSUPPRESSIVE PROPERTIES IN VIVO , 1994, Transplantation.

[23]  C. Geisler,et al.  CD3 gamma contains a phosphoserine‐dependent di‐leucine motif involved in down‐regulation of the T cell receptor. , 1994, The EMBO journal.

[24]  C. Janeway,et al.  Signals and signs for lymphocyte responses , 1994, Cell.

[25]  S. D. Gorman,et al.  The generation of a humanized, non‐mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties , 1993, European journal of immunology.

[26]  C. Ferran,et al.  IN VIVO CELL ACTIVATION FOLLOWING OKT3 ADMINISTRATION: SYSTEMIC CYTOKINE RELEASE AND MODULATION BY CORTICOSTEROIDS , 1990, Transplantation.

[27]  P. Vereerstraeten,et al.  RELEASE OF TUMOR NECROSIS FACTOR, INTERLEUKIN‐2, AND GAMMA‐INTERFERON IN SERUM AFTER INJECTION OF OKT3 MONOCLONAL ANTIBODY IN KIDNEY TRANSPLANT RECIPIENTS , 1989, Transplantation.

[28]  J. Bluestone,et al.  Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells. , 1989, Journal of immunology.

[29]  D. Droz,et al.  Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agent. , 1986, Transplantation.

[30]  M. Crumpton,et al.  Activators of protein kinase C down-regulate and phosphorylate the T3/T-cell antigen receptor complex of human T lymphocytes. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[31]  T. Mak,et al.  Reconstitution of an active surface T3/T-cell antigen receptor by DNA transfer , 1985, Nature.

[32]  A. Weiss,et al.  Requirement for the coexpression of T3 and the T cell antigen receptor on a malignant human T cell line , 1984, The Journal of experimental medicine.

[33]  R. Colvin,et al.  Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. , 1981, Transplantation.

[34]  R. Colvin,et al.  Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. , 1981, The New England journal of medicine.